Dacten

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dacten

Quick Facts

Property Description
Active ingredient Candesartan cilexetil
Form Film-coated tablet
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Blood pressure management
Origin Synthetic, non-peptide

What Type of Medicine is Dacten? (Identity and Classification)

Dacten is a prescription-only medicine whose active component is the synthetic compound Candesartan cilexetil, and it is classified as an Angiotensin II Receptor Blocker (ARB), often referred to as an Antihypertensive agent. Candesartan cilexetil is a synthetic, non-peptide compound that functions as a prodrug; it is converted to its active therapeutic component, Candesartan, upon absorption.

This class of medication is fundamental to managing the body's Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in regulating fluid and pressure balance. This classification is clinically recognized for providing effective management within the cardiovascular system.

Composition, Form, and Origin

The core composition of Dacten is the single active ingredient, Candesartan cilexetil, delivered as an oral formulation in a film-coated tablet form. The product utilizes the inactive prodrug structure, which is pharmacologically supported to enhance intestinal absorption before being converted into active Candesartan.

This compound is a laboratory-developed synthetic molecule, ensuring a standardized, predictable effect. The film-coated tablet design is a differentiating factor, as it helps facilitate swallowing and mask the taste of the components, aiding in patient adherence to the standardized delivery of the single active ingredient.

General Purpose and Action

The general purpose of Dacten is to provide targeted pharmacological management for the cardiovascular system by facilitating blood vessel relaxation. This action is achieved because the active Candesartan selectively blocks the binding of the hormone Angiotensin II to the AT1 receptor on blood vessels, preventing the mechanism that causes blood vessels to narrow (vasoconstriction).

By preventing this signal, the drug promotes vessel widening (vasodilation). This targeted effect is the fundamental mechanism that enables the continuous reduction of elevated blood pressure in adults, a use that is well-established in clinical practice.

What side effects are possible with Dacten?

Possible Side Effects and Safety Information

The official safety profile for Dacten is structured by classifying documented adverse reactions based on frequency, severity, and the body system affected, strictly according to government regulatory sources.

Adverse Reaction Scope

Adverse Reaction Type Examples (based on official classification)
Most Common (Incidence ge 2% and greater than placebo in hypertension trials) Back pain, dizziness, upper respiratory tract infection, rhinitis, pharyngitis.
Serious Adverse Reactions Syncope, hypotension, hyperkalemia, acute renal failure, and angioedema (swelling of the face, lips, throat).
System-Organ Classes Involved Nervous System (dizziness), Respiratory, Musculoskeletal, Hematologic (e.g., leukopenia, agranulocytosis - reported very rarely), and Hepatobiliary (abnormal hepatic function - reported very rarely).

Safety Restrictions and Monitoring

Official regulatory documents contain specific safety notes and limitations for Dacten:

  • Use in Pregnancy: Dacten is generally contraindicated during the second and third trimesters of pregnancy due to the documented risk of fetal injury and death. Discontinuation is required as soon as pregnancy is detected.
  • Specific Populations: Caution is required in patients with impaired hepatic or renal function. Children under one year of age must not receive the medicine for hypertension.
  • Clinical Monitoring: Close observation for signs of hypotension is necessary. Monitoring of serum potassium and renal function is also required, especially in patients with heart failure or pre-existing kidney issues. Hyperkalemia and abnormal renal function were reported more frequently as reasons for discontinuation in heart failure patients compared to hypertension patients.

Overdose and Emergency Response

The official regulatory documentation for Dacten (Candesartan cilexetil) describes the overdose profile as being dominated by exaggerated cardiovascular effects. The most frequently documented clinical sign of an overdose is profound hypotension (severely low blood pressure), often accompanied by changes in heart rate, which may include either tachycardia (fast heart rate) or, less commonly, bradycardia (slow heart rate). These physiological effects can lead to severe or life-threatening outcomes.

Potential severe manifestations listed in official labeling include syncope (fainting) and shock, which is a critical state of circulatory failure resulting from unchecked, severe symptomatic hypotension.

Regulatory authorities mandate that individuals must seek immediate medical attention for any suspected overdose. Emergency services should be contacted immediately if severe signs, such as syncope or shock, are observed.

Management for an overdose is exclusively symptomatic and supportive. The documented intervention for severe hypotension is volume expansion, typically through the administration of intravenous fluids. Other procedures, such as gastric lavage or the administration of activated charcoal, may be considered for recent ingestion. The official documentation confirms that no specific antidote is known for Candesartan cilexetil, and the active compound is not effectively removed by hemodialysis.

Therapeutic Uses of Dacten

Main Therapeutic Uses

Dacten is a medication primarily indicated for the management of symptoms associated with gastrointestinal motility disorders. Its therapeutic application is centered on the relief of discomfort caused by impaired movement within the digestive tract.

Gastric Dysmotility and Dyspepsia

The medication is frequently used to treat functional dyspepsia, a condition characterized by persistent or recurrent pain and discomfort in the upper abdomen. Patients experiencing these symptoms may find relief from the following:

  • Postprandial Fullness: A sensation of the stomach staying uncomfortably full for a long period after eating.
  • Early Satiety: Feeling full shortly after starting a meal, which may prevent the completion of a normal-sized portion.
  • Upper Abdominal Bloating: A feeling of pressure or swelling in the gastric region.
  • Nausea and Vomiting: Management of nausea and vomiting specifically related to delayed gastric emptying or other functional gastrointestinal issues.

Gastroesophageal Reflux Disease (GERD)

Dacten may be used as an adjunctive treatment for gastroesophageal reflux disease. By enhancing the coordination of the digestive muscles, it helps facilitate the downward movement of food and gastric acid, potentially reducing the frequency of acid reflux into the esophagus.

Mechanism and Benefits

The primary benefit of Dacten lies in its prokinetic properties. Unlike medications that merely neutralize stomach acid, Dacten works by stimulating the muscles of the gastrointestinal tract.

Improved Gastric Emptying

One of the central physiological benefits is the acceleration of gastric emptying. By increasing the frequency and force of contractions in the stomach and small intestine, the medication helps move contents through the digestive system more efficiently. This process is beneficial for individuals whose digestive systems naturally move too slowly, leading to chronic discomfort.

Restoration of Digestive Rhythm

By acting on specific receptors in the gut, Dacten helps restore a more natural rhythm to the digestive process. This stabilization can lead to a significant improvement in the quality of life for patients with chronic motility issues, allowing for more regular eating patterns and reduced abdominal distress.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use [Dacten] — Official Regulatory Information

The eligibility for this medication is strictly defined by regulatory bodies based on specific patient conditions and physiological states. This fixed-dose combination product is generally indicated for adult patients whose blood pressure remains uncontrolled on monotherapy.


Populations For Whom Use Is Contraindicated

Official governmental labeling states this medicine must not be used in the following groups:

  • Pregnancy and Lactation: Use is contraindicated in pregnant and breast-feeding women, as drugs of this class can cause injury or death to the developing fetus.
  • Age-Related: Contraindicated in children younger than 1 year.
  • Organ Function: Patients with severe hepatic impairment (liver failure) or severe renal impairment (creatinine clearance < 30 mL/min). Use is also prohibited in patients with anuria (absence of urine production) or cholestasis (impaired bile flow).
  • Hypersensitivity: Patients with known allergy to candesartan cilexetil, hydrochlorothiazide, or any sulfonamide-derived drugs.
  • Other Conditions: Contraindicated in patients with gout or those taking aliskiren if they have diabetes mellitus or moderate to severe renal impairment.

Eligibility Restrictions and Not Recommended Use

  • The use of this fixed-dose combination is not recommended for initial therapy to treat high blood pressure, nor is it recommended for patients with primary hyperaldosteronism.
  • Use is restricted in individuals with rare hereditary problems such as galactose intolerance due to excipient content.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Dacten (Candesartan cilexetil) define its interaction profile primarily around pharmacodynamic effects that modify the body’s fluid, electrolyte, and pressure regulation.

Interacting Substance/Class Official Regulatory Statement
Aliskiren Contraindicated in patients with diabetes or moderate-to-severe renal impairment due to the documented risks of hypotension and hyperkalemia.
ACE Inhibitors Co-administration leads to Dual RAS Blockade, increasing the risk of decreased renal function and hypotension. The triple combination with a mineralocorticoid receptor antagonist is generally not recommended.
Lithium Use with Dacten has been associated with increases in serum lithium concentrations and toxicity. Close monitoring of serum lithium levels is required during co-administration.
Potassium-Elevating Agents Substances such as potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes increase the documented risk of hyperkalemia (elevated serum potassium).
NSAIDs Non-Steroidal Anti-Inflammatory Drugs, including COX-2 selective inhibitors, may cause deterioration of renal function and attenuate the antihypertensive effect. This risk is heightened in elderly or volume-depleted patients.

Metabolic and Food Interactions: Dacten is not significantly metabolized by the Cytochrome P450 system; therefore, interactions with P450 inhibitors or substrates are not expected. The drug may be taken with or without food, as food does not alter its absorption. No mandatory time-separation rules are documented for co-administration with other interacting drugs.

Mechanism of Action

How Dacten Works — Mechanism of Action

Dacten functions as a selective Angiotensin Receptor Blocker (ARB) by binding to and blocking the Type 1 Angiotensin II Receptor ( AT1). This mechanism prevents the vasoconstrictor hormone Angiotensin II from triggering signals that promote the constriction of vascular smooth muscle and retention of sodium and water. This molecular interaction initiates a mechanistic sequence contributing to adjustments in systemic hemodynamics.

By interrupting this pathway, the drug modulates the Renin-Angiotensin-Aldosterone System (RAAS) and limits the downstream effects of Angiotensin II, specifically the stimulation of aldosterone release, a key regulator of fluid balance. The resulting physiological consequence of AT1 blockade is vasodilation and decreased salt/water reabsorption, leading to a reduction in Systemic Vascular Resistance and a decrease in overall blood volume. This change contributes to adjustments in myocardial force dynamics and results in the physiological effects of decreased cardiac pre- and afterload.

Dosage and Administration Information

How to Use Dacten (Candesartan Cilexetil): Instructions for Use

Dacten is a medication administered according to specific, standardized protocols. These instructions detail the required route, dosing schedule, and necessary adjustments.


Administration and Dosage Forms

Administration Route Dosage Form Administration Detail
Oral Use Only Film-coated Tablet (4 mg, 8 mg, 16 mg, 32 mg) Taken once daily, swallowed whole, with or without food.
Oral Suspension (for pediatric use) Prepared extemporaneously from tablets.

Standard Adult Dosing

Dosage must be individualized, and the total daily dose can range from 4 mg to 32 mg.

Condition Starting Dose (Once Daily) Maximum Recommended Daily Dose
Hypertension 16 mg 32 mg
Heart Failure 4 mg 32 mg

For Heart Failure, the dose is progressively doubled at intervals of approximately two weeks (titration) until the target dose or the highest tolerated dose is reached. The tablets can be taken with or without food.


Population-Specific Adjustments

Specific dose modifications are indicated for certain groups. A lower starting dose of 4 mg is recommended for adult patients with severe renal impairment (including those on dialysis) and for those with moderate hepatic impairment. For pediatric patients (1 to < 6 years), the dose is calculated based on weight, requiring a pharmacist-prepared oral suspension. The dose must not be doubled if a dose is missed; instead, the patient should resume the regular schedule.

Recent Clinical Evidence

Dacten: Recent Clinical Evidence


Evidence for Use in Myelodysplastic Syndromes (MDS)

Research efforts have focused on how Dacten was evaluated in studies for adult patients with Myelodysplastic Syndromes (MDS), a condition characterized by functional limitations and systemic or functional imbalance. Studies include controlled trials, where Dacten was compared to supportive care, and non-comparative studies that simply observed patient outcomes. Research examined specific changes in hematologic parameters, such as the numbers of different types of blood cells, and studies monitored specific outcomes related to blood cell function.

Findings describe patterns observed in the studies, where researchers reported measurements of hematologic responses across the groups studied. Data show patterns related to patient exposure, with study outcomes reflecting the specific, short-term treatment cycle conditions under which they were conducted. The results apply primarily to the populations studied.

Comparison of Dacten to Other Available Therapies

Studies explored how Dacten compared to a placebo (an inactive treatment) or supportive care in controlled research settings. Research describes how outcomes related to physical discomfort and systemic or functional imbalance were evaluated when Dacten was used versus when supportive care was provided. Comparative evidence against other active drug treatments is not well characterized in the studies that were reviewed. The available evidence does not offer comprehensive comparisons to all alternative treatment options.

What is Still Uncertain About Dacten Research

Key research limitations include the fact that long-term outcomes are not fully established, as follow-up durations were limited in initial studies. Data for certain groups remain insufficient, specifically for populations with significant pre-existing organ conditions or those in older patient groups. Research is ongoing to monitor and describe outcomes over extended periods. Existing research does not determine whether an individual will respond similarly to the group patterns observed in the studies.

Frequently Asked Questions (FAQ)

Common questions about Dacten (FAQ)


Q: How quickly should I expect Dacten to start working?

A: Official product information notes that the blood pressure-lowering effect may be observed within two hours of administration. However, the full, maximum effect is typically attained after approximately four weeks of continuous, consistent use.

Q: What are the most common side effects people report when taking Dacten?

A: Based on official clinical trials for hypertension, the most common side effects reported include back pain, dizziness, and symptoms related to the respiratory system, such as upper respiratory tract infection, rhinitis (inflammation of the nose), and pharyngitis (sore throat).

Q: Are there any serious side effects of Dacten I need to watch out for?

A: Official warnings specify that serious adverse reactions can occur, including symptomatic hypotension (low blood pressure with symptoms), impaired renal function (including acute kidney failure), and hyperkalemia (elevated potassium levels). Angioedema (swelling of the face, lips, or throat) is also a serious reaction that, if experienced, is typically addressed through immediate medical evaluation.

Q: Is it normal to feel tired after starting Dacten?

A: While tiredness or fatigue is not explicitly listed as a common side effect in official documents, other documented adverse reactions, such as dizziness and hypotension (low blood pressure), may cause some individuals to feel weak or tired. Individuals experiencing persistent or severe fatigue while taking any medication typically seek guidance from a healthcare provider.

Q: What are the concerns about taking Dacten while breastfeeding?

A: Official regulatory information states that it is not known whether the active component of Dacten passes into breast milk. The decision to discontinue breastfeeding or stop taking the medication is typically made by a healthcare provider, weighing the importance of the drug for the mother's health against the potential risk to the infant.

Q: Can Dacten be taken for a long time?

A: Dacten is used to manage conditions like high blood pressure, which often require long-term treatment. Official product documents note that the blood pressure-lowering effect of Dacten is sustained during long-term treatment.

Q: How long does Dacten stay in your system?

A: According to official pharmacokinetic data, the active component, candesartan, has a mean elimination half-life of approximately 9 hours. The half-life refers to the time it takes for the amount of medicine in the body to decrease by half.

Q: Is Dacten safe for people with high blood pressure?

A: Official labeling indicates that Dacten is indicated for the treatment of hypertension (high blood pressure) in adults and in children 1 year and older. The determination of whether a medication is appropriate for a specific individual is always made by a healthcare professional based on the person's full medical profile.

Q: Does Dacten have any warnings about driving or operating machinery?

A: Official patient information advises caution because Dacten may cause side effects like dizziness or light-headedness. Due to the potential for these effects, it is advised to use caution with activities like driving or operating heavy machinery until it is known how the medication affects the individual.

Q: Does Dacten need to be taken with food?

A: No, official regulatory information confirms that Dacten tablets can be taken with or without food. Taking it alongside food does not significantly affect the absorption or bioavailability of the active component.

Q: Can Dacten affect liver function?

A: The medicine is contraindicated (should not be used) in patients with severe liver impairment. Additionally, official postmarketing reports have very rarely noted occurrences of abnormal hepatic function and hepatitis (liver inflammation).

Q: Are there any clinical trials that show Dacten is better than placebo?

A: Clinical trials summarized in official documents show that Dacten has a positive placebo-subtracted effect. This means that in the study populations, the treatment produced beneficial results compared to an inactive treatment (placebo) in areas like lowering blood pressure.

Q: How often do people usually need to take Dacten?

A: For its approved uses, including hypertension and heart failure, the standard adult dosage of Dacten is typically taken once daily.

Q: Is there a generic version of Dacten available yet?

A: Yes. Dacten contains the active ingredient candesartan cilexetil, and the FDA has approved generic versions of candesartan cilexetil tablets.

Q: What should I do if a side effect of Dacten gets worse?

A: Official patient counseling information suggests contacting a healthcare provider if any side effects become severe, persistent, or bothersome. Immediate medical attention is typically recommended for clear signs of a serious reaction, such as swelling of the face or throat.

Q: What is the average duration before maximum effect of Dacten is reached?

A: According to official product information, most of the reduction in blood pressure is generally attained within four weeks of starting continuous treatment or reaching a stable dose.

Q: What foods or supplements should be avoided while on Dacten?

A: Regulatory warnings state that due to the potential for increased potassium levels (hyperkalemia), products such as potassium-containing salt substitutes and potassium supplements are typically avoided unless directed by a healthcare professional. This is because Dacten can increase potassium levels in the blood.

Q: Is Dacten known to cause stomach problems or nausea?

A: While not common, official postmarketing reports have very rarely noted general gastrointestinal disturbances in patients taking Dacten. Nausea and vomiting may also be associated with serious side effects like hyperkalemia, though they are not listed as frequent common side effects.

How should Dacten be stored and disposed of?

Official Storage and Disposal Profile

Storage and disposal instructions for Dacogen (decitabine) are strictly defined by regulatory documents to maintain drug stability and ensure handler safety.

Storage Requirements

The unopened vial must not be stored above 25 C. Once the powder is reconstituted, the concentrate must be further diluted within 15 minutes. The final diluted solution requires specialized handling, with stability permitting storage for a maximum of three hours under refrigeration (2 C-8 C), followed by up to one hour at room temperature immediately before administration. Aseptic conditions are required during preparation.

Handling and Disposal

This medicinal product is for single use only. Because it is classified as a cytotoxic agent, protective gloves must be worn, and standard procedures for handling cytotoxic medicinal products must be adopted during preparation. Any unused medicinal product or waste material must be disposed of in accordance with local requirements for cytotoxic hazardous waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dacten found in:

A-Z Index: